Silexion Therapeutics Corp (SLXN) stock
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
$1.65−0.11 (-6.25%)
Close on Nov 17, 2026Market cap $995.04KP/E –Yield –
Silexion Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $8.96, down 97.7% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.96 | -97.7% |
| FY2024 | Dec 31, 2024 | $394.94 | -93.4% |
| FY2023 | Dec 31, 2023 | $5971.05 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.70 | -68.3% |
| Q2 FY2026 | Jun 30, 2026 | $5.17 | +34.6% |
| Q1 FY2026 | Mar 31, 2026 | $0.85 | -99.7% |
| Q3 FY2025 | Sep 30, 2025 | $691.14 | +249.4% |
| Q2 FY2025 | Jun 30, 2025 | $43.19 | -97.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.84 | -96.4% |
| Q3 FY2024 | Sep 30, 2024 | $274.25 | -68.9% |
| Q2 FY2024 | Jun 30, 2024 | $197.80 | – |
| Q1 FY2024 | Mar 31, 2024 | $1659.15 | – |
| Q3 FY2023 | Sep 30, 2023 | $105.30 | – |
| Q2 FY2023 | Jun 30, 2023 | $882.90 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?